Lipid	B:C0523744
levels	I:C0523744
and	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
:	O
results	O
from	O
the	O
MEGA	O
follow	I:C0016441
-	I:C0016441
up	I:C0016441
study	I:C0016441
.	O

Lipid	O
levels	I:C0523744
and	O
risk	O
of	O
recurrent	B:C1735901
venous	I:C1735901
thrombosis	I:C1735901
:	O
results	O
from	O
the	O
MEGA	O
follow	I:C0016441
-	I:C0016441
up	I:C0016441
study	I:C0016441
.	O

Lipid	O
levels	I:C0523744
and	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
:	O
results	O
from	O
the	O
MEGA	B:C0016441
follow	I:C0016441
-	I:C0016441
up	I:C0016441
study	I:C0016441
.	O

The	O
role	O
of	O
lipid	B:C0523744
levels	I:C0523744
in	O
the	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
is	O
unclear	O
.	O

The	O
role	O
of	O
lipid	O
levels	I:C0523744
in	O
the	O
risk	O
of	O
recurrent	B:C1735901
venous	I:C1735901
thrombosis	I:C1735901
is	O
unclear	O
.	O

Lipids	B:C0023779
were	O
assessed	O
in	O
patients	O
with	O
a	O
first	O
venous	O
thrombosis	I:C0042487
(	O
n	O
=	O
2106	O
)	O
followed	O
for	O
6.9	O
years	O
.	O

Lipids	O
were	O
assessed	O
in	O
patients	O
with	O
a	O
first	O
venous	B:C0042487
thrombosis	I:C0042487
(	O
n	O
=	O
2106	O
)	O
followed	O
for	O
6.9	O
years	O
.	O

Lipids	B:C0023779
were	O
not	O
associated	O
with	O
recurrence	O
,	O
overall	O
or	O
in	O
patients	O
with	O
unprovoked	O
first	O
events	O
.	O

Testing	B:C0523744
lipid	I:C0523744
levels	I:C0523744
is	O
not	O
useful	O
to	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Background	O
Knowledge	O
of	O
risk	B:C0035648
factors	I:C0035648
for	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Background	O
Knowledge	O
of	O
risk	O
factors	I:C0035648
for	O
recurrent	B:C1735901
venous	I:C1735901
thrombosis	I:C1735901
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Background	O
Knowledge	O
of	O
risk	O
factors	I:C0035648
for	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B:C0003281
.	O

The	O
association	O
between	O
lipid	B:C0523744
levels	I:C0523744
and	O
first	O
venous	O
thrombosis	I:C0042487
has	O
been	O
studied	O
extensively	O
.	O

The	O
association	O
between	O
lipid	O
levels	I:C0523744
and	O
first	O
venous	B:C0042487
thrombosis	I:C0042487
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
data	O
on	O
the	O
role	O
of	O
lipids	B:C0023779
in	O
the	O
risk	O
of	O
recurrence	O
are	O
scarce	O
.	O

To	O
assess	O
the	O
association	O
between	O
lipid	B:C0523744
levels	I:C0523744
and	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
.	O

To	O
assess	O
the	O
association	O
between	O
lipid	O
levels	I:C0523744
and	O
recurrent	B:C1735901
venous	I:C1735901
thrombosis	I:C1735901
.	O

Patients	O
/	O
Methods	O
Patients	O
with	O
a	O
first	O
venous	B:C0042487
thrombosis	I:C0042487
from	O
the	O
MEGA	O
study	I:C0016441
were	O
included	O
.	O

Patients	O
/	O
Methods	O
Patients	O
with	O
a	O
first	O
venous	O
thrombosis	I:C0042487
from	O
the	O
MEGA	B:C0016441
study	I:C0016441
were	O
included	O
.	O

Follow	B:C1522577
-	I:C1522577
up	I:C1522577
started	O
at	O
the	O
date	O
of	O
end	O
of	O
anticoagulant	O
treatment	I:C0150457
.	O

Follow	O
-	I:C1522577
up	I:C1522577
started	O
at	O
the	O
date	O
of	O
end	B:C0444930
of	O
anticoagulant	O
treatment	I:C0150457
.	O

Follow	O
-	I:C1522577
up	I:C1522577
started	O
at	O
the	O
date	O
of	O
end	O
of	O
anticoagulant	B:C0150457
treatment	I:C0150457
.	O

Percentile	O
categories	B:C0683312
of	O
total	O
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	B:C0543421
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low	B:C0023824
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	B:C0023822
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	B:C0041004
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	B:C0003593
B	I:C0003593
and	O
A1	O
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
/	O
high	O
-	I:C0023822
density	I:C0023822
lipoprotein	I:C0023822
cholesterol	I:C0023822
,	O
triglycerides	O
and	O
apolipoproteins	O
B	I:C0003593
and	O
A1	B:C0085201
were	O
established	O
(<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Lipids	B:C0023779
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	O
anticoagulation	O
.	O

Lipids	O
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	B:C1444662
anticoagulation	O
.	O

Lipids	O
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	O
anticoagulation	B:C0003281
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	B:C0683312
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	B:C0683312
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	B:C0523744
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	B:C1517331
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	B:C0011847
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	B:C0014939
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	B:C0360714
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	O
levels	I:C0523744
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	B:C0003281
.	O

Subgroup	B:C1515021
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	O
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	O
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	O
levels	I:C0523744
studied	O
.	O

Subgroup	O
analyses	B:C0936012
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	O
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	O
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	O
levels	I:C0523744
studied	O
.	O

Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	B:C0450429
(	O
deep	O
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	O
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	O
levels	I:C0523744
studied	O
.	O

Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	B:C0149871
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	O
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	O
levels	I:C0523744
studied	O
.	O

Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	O
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	B:C0034065
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	O
levels	I:C0523744
studied	O
.	O

Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	O
vein	I:C0149871
thrombosis	I:C0149871
or	O
pulmonary	O
embolism	I:C0034065
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	B:C0523744
levels	I:C0523744
studied	O
.	O

Testing	B:C0523744
lipid	I:C0523744
levels	I:C0523744
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
in	O
this	O
study	O
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Testing	O
lipid	I:C0523744
levels	I:C0523744
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	B:C1735901
venous	I:C1735901
thrombosis	I:C1735901
in	O
this	O
study	O
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Testing	O
lipid	I:C0523744
levels	I:C0523744
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
in	O
this	O
study	B:C2603343
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Testing	O
lipid	I:C0523744
levels	I:C0523744
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	O
venous	I:C1735901
thrombosis	I:C1735901
in	O
this	O
study	O
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B:C0003281
.	O

